徠博科 LH 深 滬
等待開盤 09-17 09:30:00 美东时间
324.51
+0.540
+0.17%
華盛通- 最 高325.30
- 今 開323.51
- 成交量 56.14万股
- 最 低 320.38
- 昨 收 323.97
- 總市值 2631.78万
- 52周最高 341.075
- 市盈率 靜 31.03
- 換手率 692.22%
- 52周最低 241.64
- 委 比 -77.78%
- 總股本 8.11万
- 歷史最高 341.075
- 量 比 0.61
- 振 幅 1.52%
- 歷史最低 27.60
- 每 手 1
- 風險率 22.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Adobe绩后获多家大行齐升目标价！最高看多至270美元；甲骨文绩后现多空分歧
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从10美元升至10.5美元；摩根士丹利：维持Aurora Innovation"超配"评级，目标价从14美元升至18美元
09-14 16:05
Deal Dispatch: Bending Spoons Acquires Miro For $1.35B, Kinetik Up For Sale, LIV Golf Bankruptcy
New On The Block Kinetik Holdings Inc (NYSE:KNTK), the Blackstone-backed Delaware Basin pipeline operator, is weighing strategic alternatives, including a potential sale, Bloomberg reports. Read Also: Apptronik’s Private Market Share Soars 3,600% on Humanoid Robot Hype Updates From The Block Labcorp...
09-12 01:10
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029
Labcorp Holdings (NYSE:LH) on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day. The health care company emphasized its innovation roadmap, technological advancements and solid financial expectations for the coming years. • Labcorp Holdi...
09-11 01:40
Labcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR
Reaffirms full-year 2026 guidance Provides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5% Outlines strategic growth priorities driven by a differentiated platform powered by science, techno...
09-10 19:16
Labcorp Holdings Affirms FY2026 Adj EPS Guidance of $18.10-$18.55 vs $18.01 Est; Affirms FY2026 Sales Guidance of $14.710B-$14.827B vs $14.707B Est
Labcorp Holdings (NYSE:LH) affirms FY2026 Adj EPS guidance from $18.10-$18.55 to $18.10-$18.55 vs $18.01 analyst estimate. Affirms FY2026 sales outlook from $14.710 billion-$14.827 billion to $14.710 billion-$14.827 billion vs $14.707 billion estimate.
09-10 19:11
Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept. 9, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly ...
09-09 20:55
Labcorp buys MLM Medical Labs
Labcorp (LH) said it has acquired MLM Medical Labs, a global central and specialty laboratory provider with operations in the U.S., Germany, and South Africa. Financial terms were not disclosed. The a...
09-08 21:42
Labcorp To Offer Elecsys pTau-217 Test Following Clearance By FDA
Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings Measures phosphorylated Tau 217 (pTau-217), an indicator of amyloid pathology and a hallmark of Alzheimer's disease Intended for i...
08-24 19:08
Labcorp to Host Investor Day on September 10, 2026
BURLINGTON, N.C., Aug. 17, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investo...
08-17 20:00
